Ringworm Treatment Market Report 2026

The ringworm treatment market size has grown strongly in recent years. It will grow from $12.14 billion in 2025 to $12.82 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising prevalence of fungal skin infections, increased awareness of personal hygiene practices, growing access to retail pharmacy networks, widespread availability of topical antifungal medications, increasing diagnosis of dermatological conditions.

The ringworm treatment market size is expected to see strong growth in the next few years. It will grow to $15.79 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growing demand for effective long-term antifungal treatments, rising adoption of online pharmacy distribution, increasing focus on antifungal resistance management, expansion of combination therapy usage, growing healthcare access in emerging markets. Major trends in the forecast period include increasing demand for broad-spectrum antifungal therapies, rising use of combination drug formulations, growing preference for topical treatment options, expansion of over-the-counter antifungal products, enhanced focus on recurrence prevention strategies.

The rising prevalence of fungal infections is expected to drive the growth of the ringworm treatment market in the coming years. Fungal infections are conditions caused by the invasion or excessive growth of fungi in the body, resulting in symptoms that may affect the skin, organs, or other tissues. The increasing occurrence of fungal infections is attributed to factors such as the widespread use of immunosuppressive therapies, climate change and global warming, and the growing population of individuals with weakened immune systems. Ringworm treatments address these fungal infections by providing effective antifungal therapies that help limit transmission, reduce complications, and control infection rates, particularly among vulnerable populations. For example, in May 2025, according to the Centers for Disease Control and Prevention, a US-based public health agency, fungal diseases in the United States are associated with approximately 7,300 deaths, 130,000 hospitalizations, and 13 million outpatient visits each year, with an estimated national economic burden of around $19 billion. Therefore, the increasing incidence of fungal infections is fueling the growth of the ringworm treatment market.

The advancement of healthcare facilities is expected to further propel the growth of the ringworm treatment market going forward. Healthcare facilities include institutions such as hospitals, clinics, and diagnostic centers that provide medical care and patient support services. Improvements in healthcare facilities are being driven by increased investments in healthcare infrastructure, a stronger emphasis on patient-centered care, population growth, and aging demographics. Ringworm treatment contributes to the enhancement of healthcare facilities by promoting the development of specialized dermatological services, improving patient awareness and education regarding fungal infections, and encouraging the adoption of effective and accessible treatment options. These factors help healthcare systems expand their capacity to manage skin-related conditions more efficiently and improve overall public health outcomes. For instance, in September 2025, according to the Department of Health and Social Care, a UK-based government department, productivity across NHS acute trusts increased by 2.7% over the past year, exceeding the government’s target for the April 2024 to March 2025 period. Therefore, the improvement of healthcare facilities is supporting the growth of the ringworm treatment market.

The increasing rate of pet ownership is also expected to propel the growth of the ringworm treatment market in the coming years. Pet ownership involves the responsibility and care undertaken by individuals or households for domesticated animals, including their health, wellbeing, and daily needs. The rise in pet ownership is largely driven by the growing perception of pets as integral family members, encouraging adoption for companionship, emotional support, and improved quality of life. As pet adoption increases, the need to manage and prevent zoonotic fungal infections such as ringworm also rises. Ringworm treatments enable pet owners to effectively control fungal infections, protecting both animal health and household hygiene. For example, in March 2025, according to the American Pet Products Association (APPA), a US-based trade association, pet ownership rebounded to 94 million US households owning at least one pet, up from 82 million in 2023, with dog and cat ownership reaching 51% and 37% of households, respectively. Therefore, the growing level of pet ownership is driving the growth of the ringworm treatment market.

Major companies operating in the ringworm treatment market are Pfizer Inc., Merck And Co Inc., Bayer Healthcare, Sanofi Aventis, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Perrigo Company plc, Aurobindo Pharma Ltd, Dr Reddys Laboratories Ltd, Cipla Ltd, Intas Pharmaceuticals Ltd, Zydus Group, Glenmark Pharmaceuticals Inc, Biocon Limited, Torrent Pharmaceuticals Ltd, Taro Pharmaceutical Industries Ltd, Lupin Limited, Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals plc, Alkem Laboratories Ltd, Mankind Pharma Ltd.

North America was the largest region in the ringworm treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ringworm treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ringworm treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the ringworm treatment market by increasing the cost of imported active pharmaceutical ingredients, excipients, packaging materials, and finished antifungal formulations used across topical and oral therapies. Pharmaceutical manufacturers in North America and Europe are most affected due to dependence on imported APIs, while Asia-Pacific faces pricing pressure on export-oriented drug production. These tariffs are contributing to higher treatment costs and margin pressures for generic drug manufacturers. However, they are also encouraging domestic API manufacturing, regional sourcing strategies, and increased investment in local pharmaceutical production capabilities.

The ringworm treatment market research report is one of a series of new reports that provides ringworm treatment market statistics, including ringworm treatment industry global market size, regional shares, competitors with a ringworm treatment market share, detailed ringworm treatment market segments, market trends and opportunities, and any further data you may need to thrive in the ringworm treatment industry. This ringworm treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ringworm treatment involves the use of medications to eradicate fungal infections caused by dermatophytes, alleviate symptoms such as itching and redness, and prevent the spread of this contagious condition to other parts of the body or to other individuals. Along with medication, maintaining good hygiene, keeping affected areas dry, and avoiding direct contact with infected people or contaminated surfaces help manage the condition and reduce the risk of recurrence.

The main drug classes used in ringworm treatment include antifungals and combination drugs. Antifungals are medications formulated to prevent, control, or eliminate fungal infections by targeting fungal cells while minimizing harm to the host. These treatments cover various conditions such as tinea corporis, tinea pedis, tinea cruris, tinea capitis, tinea manuum, and others, and are administered through routes including topical, oral, and parenteral. They are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The ringworm treatment market consists of sales of adjunctive treatment, azoles, and allylamines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.